Friday, April 3, 2026
30.4 C
Bengaluru

Pharma CEO Roundtable – Engaging Doctors – Physical, Digital and Hybrid: Translating Strategy into Action

The MedicinMan 10th Anniversary Special – Pharma CEO Roundtable 2021 Series 2 is Now Live

Pharma CEO Roundtable – Engaging Doctors – Physical, Digital and Hybrid: Translating Strategy into Action

Keynote Speaker: Dr. Mahender Nayak, Senior VP / Head of ICMEA* Region (India, Turkey, CIS Countries, Ukraine, Middle East & Africa) at Takeda.

Panel Members: Prakash Maheshwari, Vice President, Glenmark: Strategic Leadership | Pill+Service | Building Talent | Change Management | Risk-Taking & Innovation.

Sourabh Agrawal, Vice President – Sales & Marketing at Lupin Global.

Salil Kallianpur, Executive Editor of MedicinMan and former Executive VP – Emerging Markets at GSK.

Praful Akali, MD at Medulla Communications

– https://youtu.be/fYYdoXHBaW8 via YouTube

Hot this week

Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India

How the 2026 U.S. tariff action on branded drugs...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Topics

Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?

As over 50 generic versions of the blockbuster weight-loss...
spot_img

Related Articles

spot_imgspot_img